(Reuters) - Roche Holding AG will cut the price of two cancer drugs in India from 2013, the Wall Street Journal reported on Friday, days after an Indian drugmaker was allowed to make and sell a blockbuster cancer drug at a fraction of its market price. Tuygan Goeker, head of Middle East and Asian markets at Roche, named the drugs as Herceptin and Mabthera, the wholesale costs of which are about $3,000 to $4,500 a month per patient. ...
Source: news.yahoo.com
No comments:
Post a Comment